CSL 미래 성장

Future 기준 확인 3/6

CSL (는) 각각 연간 13% 및 6.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.5% 로 예상됩니다.

주요 정보

13.0%

수익 성장률

13.0%

EPS 성장률

Biotechs 수익 성장	15.5%
매출 성장률	6.5%
향후 자기자본 수익률	18.5%
애널리스트 커버리지	Good
마지막 업데이트	28 Nov 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

CHIA:CSL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2027	18,024	4,131	4,113	4,958	14
6/30/2026	16,883	3,619	3,588	4,362	15
6/30/2025	15,760	3,095	2,966	3,797	15
6/30/2024	14,800	2,642	1,506	2,764	N/A
3/31/2024	14,490	2,557	1,332	2,727	N/A
12/31/2023	14,179	2,472	1,158	2,690	N/A
9/30/2023	13,745	2,333	1,034	2,646	N/A
6/30/2023	13,310	2,194	909	2,601	N/A
3/31/2023	12,507	2,156	765	2,392	N/A
12/31/2022	11,705	2,118	622	2,182	N/A
9/30/2022	11,133	2,186	1,001	2,406	N/A
6/30/2022	10,562	2,255	1,381	2,629	N/A
3/31/2022	10,587	2,290	1,251	2,679	N/A
12/31/2021	10,612	2,325	1,121	2,728	N/A
9/30/2021	10,461	2,350	1,538	3,175	N/A
6/30/2021	10,310	2,375	1,955	3,622	N/A
3/31/2021	10,145	2,520	2,127	3,597	N/A
12/31/2020	9,980	2,665	2,299	3,571	N/A
9/30/2020	9,565	2,384	1,710	3,030	N/A
6/30/2020	9,151	2,103	1,121	2,488	N/A
3/31/2020	9,048	2,054	1,009	2,418	N/A
12/31/2019	8,944	2,006	897	2,347	N/A
9/30/2019	8,742	1,962	628	1,996	N/A
6/30/2019	8,539	1,919	360	1,644	N/A
3/31/2019	8,406	1,861	426	1,621	N/A
12/31/2018	8,274	1,803	492	1,597	N/A
9/30/2018	8,094	1,766	701	1,750	N/A
6/30/2018	7,915	1,729	910	1,902	N/A
3/31/2018	7,666	1,674	N/A	1,662	N/A
12/31/2017	7,417	1,618	N/A	1,422	N/A
9/30/2017	7,182	1,478	N/A	1,335	N/A
6/30/2017	6,947	1,337	N/A	1,247	N/A
3/31/2017	6,802	1,333	N/A	1,192	N/A
12/31/2016	6,656	1,329	N/A	1,138	N/A
9/30/2016	6,386	1,286	N/A	1,158	N/A
6/30/2016	6,115	1,242	N/A	1,179	N/A
3/31/2016	5,983	1,324	N/A	1,296	N/A
12/31/2015	5,850	1,406	N/A	1,413	N/A
9/30/2015	5,654	1,392	N/A	1,388	N/A
6/30/2015	5,459	1,379	N/A	1,364	N/A
3/31/2015	5,482	1,366	N/A	1,434	N/A
12/31/2014	5,505	1,354	N/A	1,504	N/A
9/30/2014	5,420	1,330	N/A	1,432	N/A
6/30/2014	5,335	1,307	N/A	1,361	N/A
3/31/2014	5,189	1,270	N/A	1,257	N/A
12/31/2013	5,042	1,233	N/A	1,154	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CSL 의 연간 예상 수익 증가율( 13% )이 saving rate( 2.6% 보다 높습니다. ).

수익 vs 시장: CSL 의 연간 수익( 13% ) Australian 시장( 12.6% 보다 빠르게 성장할 것으로 예상됩니다. 12.6% 연간).

고성장 수익: CSL 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: CSL 의 수익(연간 6.5% ) Australian 시장( 5.8% 보다 빠르게 성장할 것으로 예상됩니다. 5.8% 연간).

고성장 수익: CSL 의 수익(연간 6.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CSL 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 18.5 %).

CSL 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited Provides Financial Guidance for Fiscal 2022

Recent updates

MD, CEO & Executive Director recently sold AU$1.1m worth of stock

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

Upcoming dividend of US$1.45 per share

Final dividend of US$1.45 announced

Full year 2024 earnings released: EPS: US$5.47 (vs US$4.55 in FY 2023)

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings released: EPS: US$4.55 (vs US$4.81 in FY 2022)

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

Upcoming dividend of US$1.07 per share at 1.1% yield

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

Independent Non Executive Director recently bought AU$74k worth of stock

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

Non-Independent Non-Executive Director recently sold AU$6.4m worth of stock

Upcoming dividend of US$1.18 per share

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

Full year 2022 earnings released: EPS: US$4.81 (vs US$5.22 in FY 2021)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

Now 20% undervalued

Now 21% undervalued after recent price drop

Upcoming dividend of US$1.04 per share

Independent Non-Executive Director recently bought AU$54k worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

MD, CEO & Executive Director recently sold AU$4.4m worth of stock

MD, CEO & Executive Director recently sold AU$4.8m worth of stock

High number of new directors

Upcoming dividend of US$1.18 per share

Full year 2021 earnings released: EPS US$5.22 (vs US$4.63 in FY 2020)

CSL Limited Provides Financial Guidance for Fiscal 2022

Independent Non-Executive Director Shah Hussain has left the company

Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older

Independent Non-Executive Chairman recently bought AU$82k worth of stock

New 90-day low: AU$263

First half 2021 earnings released: EPS US$3.98 (vs US$2.75 in 1H 2020)